Sökresultat
Alexion presenterar nya data på AAN
…MOSD). New findings from CHAMPION-NMOSD trial will reinforce the potential for Ultomiris to eliminate relapses and improve care in AQP4 Ab+ NMOSD. Long-term data and real-world evidence in gMG will underscore vital role of Ultomiris and Soliris in treatment landscape and show sustained patient benefit. Presentations include new long-term results from the pivotal Phase III CHAMPION-MG and CHAMPION-NMOSD trials, as well as real-world data, adding to…
Livskvalitet och resursutnyttjande vid Parkinsons
…England Scale, and NMSS were statistically significant predicting factors for total costs. Conclusion Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients. Read more and download the article Acta Neurologica Scandinavica, 2022; 00: 1-10 DOI: 10.1111/ane.1…
Cancerläkemedel kan stoppa spridningen av Parkinsons sjukdom
…ll Engineering. Long-standing studies have shown that by clumping together and forming protein deposits, misfolded alpha-synuclein proteins journey from brain cell to brain cell, killing those responsible for producing a neurotransmitter called dopamine, and causing Parkinson’s disease to progress through a type of “programmed” cell death that Johns Hopkins researchers have identified. The process, parthanatos (from the Greek word for “death”), le…
Europeiska kommissionen godkänner VIMPAT® för behandling av primär generaliserade tonisk-kloniska anfall
…Seizure 2012;21:165–8. 6. DeGiorgio CM, et al. Ranking the leading risk factors for sudden unexpected death in epilepsy. Front Neurol. 2017;8:473 7. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), October 16, 2020, https://www.ema.europa.eu/en/medicines/human/summaries-opinion/vimpat 8. Vossler DG, et al. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic…
Ultomiris rekommenderas för godkännande i EU av CHMP för behandling av vuxna med generell myasthenia gravis
…ositiv rekommendation för marknadsgodkännande av CHMP som ett tillägg till standard therapy för behandlingen av vuxna patienter med generel myasthenia gravis (gMG) som är anti-acetylcholine receptor (AChR) antibody-positive. Vid godkännandet blir Ultomiris den första långverkande C5 complement hämmaren i EU. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the CHA…